Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720494 | 0.87 | MAPT (0.72) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12132347 | 0.86 | MAPT (0.66) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20267376 | 0.86 | MAPT (0.53) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18703938 | 0.86 | MAPT (0.66) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL900124 | 0.85 | MAPT (0.70) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14081979 | 0.84 | MAPT (0.51) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6983298 | 0.84 | MAPT (0.68) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16809642 | 0.84 | MAPT (0.68) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12297020 | 0.84 | ALDH1A1 (0.69) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13130067 | 0.84 | MAPT (0.68) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026486-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20200299425-A1 | ACTIVE ENERGY RAY CURABLE COMPOSITION, ACTIVE ENERGY RAY CURABLE INK, COMPOSITION ACCOMMODATING CONTAINER, TWO OR THREE DIMENSIONAL IMAGE FORMING APPARATUS, TWO OR THREE DIMENSIONAL IMAGE FORMING METHOD, CURED MATTER, DECORATIVE MATTER, ARTIFICIAL NAIL COMPOSITION, NAIL DECORATIVE MATERIAL, AND ARTIFICIAL NAIL | RICOH COMPANY, LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-9458171-B2 | Pyrrolidinyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| EP-2482793-B1 | USE OF PIPERIDINE ESTER DERIVATIVE AS SOLVENT IN COSMETIC COMPOSITIONS; COSMETIC COMPOSITIONS COMPRISING IT | ORÉAL L (FR) | 2015-04-22 | — | — | EP | disclosed |
| US-20120282197-A1 | USE OF PIPERIDINE ESTER DERIVATIVE AS SOLVENT IN COSMETIC COMPOSITIONS; COSMETIC COMPOSITIONS COMPRISING IT | L'OREAL (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120282197-A1 | USE OF PIPERIDINE ESTER DERIVATIVE AS SOLVENT IN COSMETIC COMPOSITIONS; COSMETIC COMPOSITIONS COMPRISING IT | L'OREAL (FR) | 2012-11-08 | — | — | US | disclosed |
| WO-2011038776-A1 | USE OF PIPERIDINE ESTER DERIVATIVE AS SOLVENT IN COSMETIC COMPOSITIONS; COSMETIC COMPOSITIONS COMPRISING IT | L'OREAL (FR) | 2011-04-07 | — | — | WO | disclosed |
| WO-2009105746-A2 | TRIAZOLES AND PROCESSES FOR PRODUCING THE SAME | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-08-27 | — | — | WO | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
| WO-2004014910-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-02-19 | — | — | WO | disclosed |
| EP-0985671-B1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARM CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-6197768-B1 | THERAPY, PREVENTION ISCHEMIC HEART DISEASE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0985671-A1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-6018046-A | SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| US-4886794-A | ANTIHISTAMINES, ANTIALLERGENS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282197-A1 | USE OF PIPERIDINE ESTER DERIVATIVE AS SOLVENT IN COSMETIC COMPOSITIONS; COSMETIC COMPOSITIONS COMPRISING IT | PLD1, PLD2, FFAR1 | MAPT 4114/4885ALDH1A1 49/4885CYP3A4 1139/4885 |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | MAPT 96/4885ALDH1A1 944/4885CYP3A4 1271/4885 |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | RORC, RORB, RORA | MAPT 385/4885ALDH1A1 1327/4885CYP3A4 387/4885 |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | RORC, RORB, RORA | MAPT 314/4885ALDH1A1 1269/4885CYP3A4 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.